WO2003072043A3 - Procede de reduction des effets secondaires d'agents anticancereux - Google Patents

Procede de reduction des effets secondaires d'agents anticancereux Download PDF

Info

Publication number
WO2003072043A3
WO2003072043A3 PCT/US2003/005482 US0305482W WO03072043A3 WO 2003072043 A3 WO2003072043 A3 WO 2003072043A3 US 0305482 W US0305482 W US 0305482W WO 03072043 A3 WO03072043 A3 WO 03072043A3
Authority
WO
WIPO (PCT)
Prior art keywords
recuding
side effects
neoplastic agent
induced side
agent induced
Prior art date
Application number
PCT/US2003/005482
Other languages
English (en)
Other versions
WO2003072043A2 (fr
Inventor
Hideo Kikkawa
Mine Kinoshita
Mariko Maeda
Akiko Mizukami
Kazunori Ozawa
Original Assignee
Smithkline Beecham Corp
Hideo Kikkawa
Mine Kinoshita
Mariko Maeda
Akiko Mizukami
Kazunori Ozawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Hideo Kikkawa, Mine Kinoshita, Mariko Maeda, Akiko Mizukami, Kazunori Ozawa filed Critical Smithkline Beecham Corp
Priority to AU2003217669A priority Critical patent/AU2003217669A1/en
Publication of WO2003072043A2 publication Critical patent/WO2003072043A2/fr
Publication of WO2003072043A3 publication Critical patent/WO2003072043A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé de réduction de la néphrotoxicité et des diarrhées causées, chez un mammifère, par des agents anticancéreux, à l'aide d'un inhibiteur de phosphodiestérase 4 (PDE4).
PCT/US2003/005482 2002-02-25 2003-02-21 Procede de reduction des effets secondaires d'agents anticancereux WO2003072043A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003217669A AU2003217669A1 (en) 2002-02-25 2003-02-21 A method of recuding anti-neoplastic agent induced side effects

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35934602P 2002-02-25 2002-02-25
US60/359,346 2002-02-25

Publications (2)

Publication Number Publication Date
WO2003072043A2 WO2003072043A2 (fr) 2003-09-04
WO2003072043A3 true WO2003072043A3 (fr) 2004-03-04

Family

ID=27766068

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/005482 WO2003072043A2 (fr) 2002-02-25 2003-02-21 Procede de reduction des effets secondaires d'agents anticancereux

Country Status (2)

Country Link
AU (1) AU2003217669A1 (fr)
WO (1) WO2003072043A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109908139B (zh) * 2018-12-28 2022-02-22 南京市儿童医院 西洛司特在制备用于治疗急性肾损伤相关病症的药物中的用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5550101B2 (ja) * 2007-02-12 2014-07-16 ヴィリックス ファーマシューティカルズ インコーポレイテッド トラマドールの副作用の低減薬の製造におけるトラマドールおよびｐｄｅ阻害剤の使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156753A (en) * 1997-10-28 2000-12-05 Vivus, Inc. Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156753A (en) * 1997-10-28 2000-12-05 Vivus, Inc. Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109908139B (zh) * 2018-12-28 2022-02-22 南京市儿童医院 西洛司特在制备用于治疗急性肾损伤相关病症的药物中的用途

Also Published As

Publication number Publication date
WO2003072043A2 (fr) 2003-09-04
AU2003217669A8 (en) 2003-09-09
AU2003217669A1 (en) 2003-09-09

Similar Documents

Publication Publication Date Title
WO2004018431A3 (fr) Nouvelles phenanthridines
WO2002072022A3 (fr) Composes de tetracycline substitues, en tant qu'agents antifongiques
HK1064668A1 (en) Polycyclic guanine phosphodiesterase v inhibitors
PL368286A1 (en) Naphtyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
AU5466601A (en) Method for providing metal surfaces with protection against corrosion
WO2004018465A3 (fr) Nouvelles benzonaphtyridines
EP1442028A4 (fr) Derives d'acides substitues en tant qu'agents de lutte contre le diabete et contre l'obesite, et procede associe
AP2006003708A0 (en) Methods and compositions for treating flavivirusesand pestiviruses
MXPA04006275A (es) Composiciones farmaceuticas que comprenden un inhibidor de fosfodiesterasa multifuncional y un inhibidor de captacion de adenosina.
IL179686A0 (en) Combinations comprising antimuscarinig agents and pde4 inhibitors
AU2001245977A1 (en) Method and composition for preventing or reducing the symptoms of menopause
GB0114185D0 (en) Compounds
NO995578D0 (no) Korrosjonsinhibitor sammenstillinger samt metode for å fremstille disse
EP1390363A4 (fr) Derives acides d'azole substitue utiles comme agents antidiabetiques et agents contre l'obesite et procede apparente
AU2003297573A8 (en) Compositions and methods for treating transplants
CA2398389A1 (fr) Methode d'inhibition d'une tumeur
WO2003072043A3 (fr) Procede de reduction des effets secondaires d'agents anticancereux
AU2001273318A1 (en) Methods and compositions for diagnosing and treating preeclampsia and gestational trophoblast disorders
DK1490024T3 (da) Alendronatholdige brusesammensætninger
AU2001290710A1 (en) Method for increasing the effectiveness of antiinfective agents
AR029984A1 (es) Metodo para reducir las exacerbaciones asociadas copd ambito
AU2002360565A8 (en) Compositions and methods for normalizing assays
AU2001278135A1 (en) Method of identifying immunosuppressive agents
AU2002362316A1 (en) A method and kit for the measurement of the activation of basophils induced by allergen to determine hypersensitivity
AU2001236100A1 (en) Vasoactive agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP